Table 2.

Comparison result at the end of treatment: CHM VS Control group, within 2 groups.

Comparison	Participants; Duration (in weeks)	Change between CHM and Control Group MD (95% CI)	Change within CHM group; MD (95% CI)	Change within Control group; MD (95% CI)
1. CHM vs Placebo
Zhang 2016	96;60	1.33 [−0.34,3.00]	0.68 [−0.80,2.16]	−1.32[−2.52, −0.12]
Zhang 2014	12;28	0.68 [−0.67,2.03]	1.50 [0.52, 2.48]	0.50 [−0.95, 1.95]
Zhou 2007	48;79	0.64 [−0.09,1.37]	2.22 [1.68, 2.76]	1.81 [1.11. 2.51]
Wu 2016	12;78	2.53 [0.92, 4.14]	1.35 [0.68, 2.02]	−0.60 [−2.77,1.57]
2. CHM vs Other drugs
CHM vs Nimodipine
Zhang 2018	12;60	3.15 [1.30, 5.00]	4.68 [2.17,7.19]	2.12 [0.79, 3.45]
Zhao 2009	12;60	0.32 [−0.09, 0.73]	1.35 [0.68,2.02]	−0.60 [−2.77,1.57]
Cui 2015	12;32	0.13 [−0.92,1.18]	2.00 [1.16, 2.84]	2.06 [1.16, 2.96]
CHM vs Aniracetam
Guo 2010	12;64	1.09 [0.18, 2.00]	2.91 [2.21, 3.61]	1.94 [1.24, 2.64]
Zhong 2007	12;166	−0.06 [−0.61, 0.49]	0.77 [0.16, 1.38]	0.57 [0.01, 1.13]
Gu2015	12;100	−0.39 [−1.04, 0.26]	1.00 [0.13, 1.87]	0.63 [0.02, 1.24]
Chen 2016	12;86	0.24 [−0.41, 0.89]	0.42 [−0.04, 0.88]	0.97 [0.41, 1.53]
Wang 2011	12;80	1.41 [0.44, 2.38]	3.40 [2.47, 4.33]	1.68 [0.73, 2.63]
CHM vs Piracetam
Zhu 2010	12;100	0.90 [0.37, 1.43]	2.48 [1.94, 3.02]	1.58 [1.04, 2.12]
Li 2016	12;60	0.29 [−0.23, 0.81]	1.00 [0.49, 1.51]	−0.97 [−1.44, −0.50]
CHM vs Donepezil
Lin 2020	12;88	−0.21 [−0.95,0.53]	1.57 [0.79, 2.35]	1.57 [0.84, 2.03]
Miao 2012	12;72	−0.17 [−0.80, 0.46]	0.11 [−0.34, 0.56]	0.36 [−0.48, 1.20]
CHM vs Huperzine
Chen 2017	24;69	0.54 [−049, 1.57]	1.72 [1.47,1.97]	2.22 [2.03, 241]
Sheng 2016	24;64	0.03 [−0.22, 0.28]	2.63 [1.35,3.91]	2.18 [1.16, 3.20]
3. CHM + Other drugs vs Other drugs
Wang 2012	12;52	2.72 [0.32, 5.12]	4.68 [2.17,7.19]	2.12 [0.79, 3.45]
Xu 2013	12;60	1.00 [−0.14, 2.14]	1.40 [0.50,2.30]	0.42 [0.52, 1.36]
Wu 2017	8;102	3.94 [3.52, 4.36]	8.15 [7.62,8.68]	4.04 [3,48, 4.60]